VJHemOnc

GPRC5D-directed therapies are reshaping the #MultipleMyeloma treatment landscape.🩸

Explore practical considerations with the use of GPRC5D-directed agents in our interactive expert feature. 🔍

Click here:
📖 buff.ly/PKlan0C

#MMsm #Myeloma #CellTherapy #ImmunoOnc #GPRC5D #HemOnc #BloodSky

🎥 Shaji Kumar discusses the safety & efficacy of talquetamab & teclistamab in patients with R/R #MultipleMyeloma and EMD, highlighting findings from the RedirecTT-1 study:

👉 buff.ly/fibdR27 👈

#MMSM #Myeloma #HemOnc #CTSM #TrialUpdate #ImmunoOnc #BloodSky #HemeSky #MedSky

In an interview from #18ICML, Nikhil Mankuzhy of @mskcancercenter.bsky.social provides insight into the efficacy of response-adapted very low-dose radiotherapy at a dose of 4 Gy for indolent #NonHodgkinLymphoma:

🎥 buff.ly/bLGk41w

#LYMsm #Lymphoma #RadOnc #HemOnc #BloodSky #HemeSky #MedSky

We recently caught up with Farhad Ravandi of @mdanderson.bsky.social, who spoke on the current standard of treatment for older or unfit patients with AML and outlined future directions in this patient population.

Watch here:

🎥 buff.ly/t3ELfZa

#AMLsm #Leusm #Leukemia #HemOnc #EHA2025 #BloodSky

The PhII EpLCART trial is assessing the feasibility of ctDNA-directed epcoritamab with/without R-squared in pts with LBCL at high risk of relapse in the early post-CAR-T setting.

Hear more from Mark Dowling of @petermaccc.bsky.social:

🎥 buff.ly/lpWzIFc

#LYMsm #CTSM #ImmunoOnc #MedSky #BloodSky

Watch our recent interview with Jae Park of @mskcancercenter.bsky.social to hear about the long-term data with obe-cel in ALL & its potential to serve as a standalone treatment for adult R/R B-ALL.

Click here:

👉 buff.ly/inx0gbp

#ALLsm #Leusm #Leukemia #CTSM #CARTCell #ImmunoOnc #HemOnc

🚨We've just published a new podcast episode!

This episode compiles some of our highlights from #iwMPN25, covering novel frontline approaches to #Myelofibrosis management, cardiovascular health in MPNs & the application of AI in the space. 🎧

Listen now 👉 buff.ly/9RGGuct

#MPNsm #HemOnc #BloodSky

Want to hear about updates & advances in MDS classification & risk stratification?🩸

Watch our fantastic roundtable discussion from #iwMDS25 with experts Uma Borate, Luca Lanino, Robert Hasserjian, & @zoeyxie.bsky.social:

🎥 buff.ly/Yr2mKl8

#MDSsm #HemOnc #BloodSky #HemeSky #MedSky

🎥 Pinkal Desai of @weillcornell.bsky.social discusses healthcare resource utilization in newly diagnosed patients with AML treated with venetoclax compared with high- or low-intensity non-venetoclax therapies:

👉 buff.ly/O6dmk8i 👈

#AMLsm #Leusm #Leukemia #HemOnc #EHA2025 #MedSky #BloodSky

What is the MPN Workshop of the Carolinas, and why should you register?🤔🩸

Hear from course director @rubenmesamd.bsky.social as he invites you to attend this fantastic event in-person or virtually on August 22-23:

🎥 buff.ly/4Ja8SF6

Click below to register:
🔗 buff.ly/CTlggp7

#MPNsm #HemOnc

What are some of the most exciting developments in the field of Waldenström’s macroglobulinemia?🩸

We caught up with Steven Treon of @danafarber.bsky.social at #18ICML to find out!

Watch the interview here:

👉 buff.ly/WoIXa0k 👈

#LYMsm #Lymphoma #HemOnc #BloodSky #MedSky #HemeSky

In a fantastic discussion at #iwCART25 earlier this year, experts David Miklos, Frederick Locke, Lazaros Lekakis, & Sarah Nikiforow shared insights into the application of cell therapy to autoimmune diseases.

Click here to watch:
👉 buff.ly/AUZp3Cb 👈

#Hematology #CARTCell #BloodSky #HemeSky #MedSky

It was fantastic to speak with Kathryn Tringale to hear about the treatment paradigm for primary CNS #lymphoma.🎥

Prof. Tringale discussed consolidation options, comparing autoSCT & reduced-dose whole-brain radiation:

👉 buff.ly/kNYJF3j 👈

#LYMsm #HemOnc #MedSky #BloodSky #HemeSky

🎥 Hear about the clinical issue of hidden light chain #amyloidosis in patients with #MultipleMyeloma in an interview with Ashutosh Wechalekar from #EHA2025:

👉 buff.ly/D1VyeXd 👈

#MMSM #Myeloma #HemOnc #BloodSky #HemeSky #MedSky

Want to hear about the recent publication of the updated LYSA guidelines for the diagnosis and management of primary mediastinal B-cell #lymphoma?🩸

Check out our interview from #18ICML with Vincent Camus:

👉 buff.ly/sFZ0XoZ 👈

#LYMsm #HemOnc #BloodSky #HemeSky #MedSky

#EHA2025 | Paul Richardson of @danafarber.bsky.social comments on the effectiveness of mezigdomide in novel combinations for reactivating the immune system in patients with R/R #MultipleMyeloma:

🎥 buff.ly/3MFWK1V

#MMSM #Myeloma #HemOnc #BloodSky #HemeSky #MedSky

Watch our interview from #18ICML to hear about the safety & efficacy of mosunetuzumab treatment in previously untreated #FollicularLymphoma & marginal zone #lymphoma from Adam Olszewski:

🎥 buff.ly/1yymrHB

#LYMsm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

We recently spoke with Francesca Palandri, who highlighted the prognostic relevance of the ELN clinical signs and symptoms in patients with polycythemia vera treated with hydroxyurea or ruxolitinib.🩸

Click to watch:
🎥 buff.ly/SyPomC1

#MPNsm #HemOnc #BloodSky #HemeSky #MedSky

At #EHA2025, we interviewed Max Rieger to hear about a study evaluating the effectiveness of venetoclax in treating advanced-stage R/R AL #amyloidosis with cardiac involvement & t(11;14).

Click here to learn more:

👉 buff.ly/kBC6c3U

#HemOnc #BloodSky #HemeSky #MedSky

It was a pleasure to speak with Karan Chohan of @mdanderson.bsky.social at #18ICML to hear about the long-term outcomes of patients with Waldenström’s macroglobulinemia who discontinue BTKi therapy.🩸

Click here to watch the interview:
👉 buff.ly/tKePX7s

#LYMsm #Lymphoma #HemOnc

In a recent interview, Alaa Ali provided valuable insight into selecting between CAR T-cell products for treating LBCL.💉🩸

Click here to learn more:

👉 buff.ly/DLmjhkP 👈

#CARTCell #ImmunoOnc #LYMsm #DLBCL #HemOnc #18ICML #Lymphoma

It was wonderful to catch up with Joshua Zeidner at #EHA2025 to hear the updated results from the Beat AML Master trial of revumenib + aza-ven in older adults with NPM1-mutated or KMT2A-rearranged AML.

Watch here:
👉 buff.ly/sT0CECq

#AMLsm #Leusm #CTSM #BloodSky #HemeSky @leukdocjz.bsky.social

Want to hear about updates & advances in MDS classification & risk stratification?🩸

Watch our fantastic roundtable discussion from #iwMDS25 with experts Uma Borate, Luca Lanino, Robert Hasserjian, & Zhuoer Xie:

🎥 buff.ly/UtUKM0w

#MDSsm #HemOnc #BloodSky #HemeSky #MedSky

#iwMPN25 | Alexander Lyon discusses cardiovascular health in patients with MPNs, and provides insight into risk stratification & management strategies.🫀🩸

Click here to watch the interview:

👉 buff.ly/CxamPIw 👈

#MPNsm #HemOnc #BloodSky #HemeSky #MedSky

Can we target mutant CALR in MPNs for real disease modification?

In this podcast episode, the experts discuss:
🧬 Therapeutic antibodies
🧫 Cellular therapies
🔍 Trial updates

🎧 A must-listen for HCPs in hemonc: buff.ly/VaEw96e

#MPNsm #HemOnc #Myelofibrosis #BloodSky #HemeSky #MedSky

Watch our interview from #EHA2025 with Shambavi Richard of @TischCancer to hear findings from the ongoing Phase I/IIa trial investigating HDP-101, a novel BCMA-targeting antibody-drug conjugate, in #MultipleMyeloma:

🎥 buff.ly/QdLRjUe

#MMSM #Myeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky

The MPN Workshop of the Carolinas aims to provide up-to-date information about the pathogenesis & management of MPNs to practicing clinicians & to foster discussion to improve outcomes for patients.🩸

Register for the in-person event or the webinar here:
👉 buff.ly/tiCjJPk

#MPNsm #HemOnc #BloodSky

At #EHA2025, we had the opportunity to catch up with Amir Fathi to hear the promising results of the Phase Ib/II KOMET-001 study of ziftomenib in R/R NPM1-mutant AML.

Check out the interview here:

👉 buff.ly/IlVeBKE

#AMLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky

In a fantastic recent interview, Ali Bazarbachi discusses findings from a large retrospective analysis evaluating changes in transplant outcomes over time in relapsed #HodgkinLymphoma.🩸

Click here to watch:
👉 buff.ly/VLWteuI 👈

#LYMsm #BMTsm #HemOnc #BloodSky #HemeSky #MedSky

The PREDATOR-MRD trial was a Phase II study evaluating the efficacy of single-agent daratumumab versus observation in patients with MRD recurrence of #MultipleMyeloma.🩸

Hear the results of this trial from Krzysztof Jamroziak:

👉 buff.ly/9YNECGE

#MMSM #Myeloma #mmMRD #BloodSky #HemeSky #MedSky